GO:0071659 negative regulation of IP-10 production: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071659 describes any process that stops, prevents, or reduces the production of IP-10 (CXCL10), a key interferon-inducible chemokine.
• IP-10/CXCL10 is strongly induced by IFN-α and IFN-γ and is a biomarker of immune activation in HIV and COVID-19.
• Negative regulators such as SLAMF7 and SHIP-1 dampen IFN-driven CXCL10 production in monocytes and macrophages.
• IL-4 suppresses IP-10 gene expression in murine macrophages, providing an early model of negative regulation.
• PTP1B negatively regulates STAT1-independent macrophage killing and may influence chemokine output.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect causal regulators of IP-10 production.
Description
GO:0071659, negative regulation of IP-10 production, is a biological process that reduces the frequency, rate, or extent of production of the chemokine IP-10 (also known as CXCL10). IP-10 is a small secreted protein that attracts activated T cells and is induced by interferons during antiviral and inflammatory responses. Because excessive IP-10 production drives immunopathology in chronic infections and autoimmune conditions, understanding its negative regulation is critical for therapeutic intervention. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to describe the mechanisms, key genes, disease links, and experimental models for studying GO:0071659.
negative regulation of IP-10 production At A Glance
| GO ID | GO:0071659 |
|---|---|
| GO term | negative regulation of IP-10 production |
| Ontology | biological_process |
| Synonym | negative regulation of chemokine (C-C motif) ligand 10 production; negative regulation of CXCL10 production |
| Major function | Suppression of IP-10/CXCL10 chemokine production, limiting immune cell recruitment and inflammation |
| Key regulators | SLAMF7, SHIP-1, IL-4, PTP1B |
| Associated diseases | HIV infection, COVID-19, inflammatory disorders |
| Research methods | CRISPR knockout, RNA-seq, ELISA, flow cytometry |
What Is GO:0071659?
According to the Gene Ontology, GO:0071659 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of production of IP-10. IP-10, also called CXCL10, is a chemokine that is produced by many cell types in response to interferon signaling. Negative regulation of IP-10 production therefore encompasses molecular events that suppress CXCL10 gene transcription, mRNA stability, or protein secretion, ultimately lowering the amount of IP-10 available to recruit immune cells.
Why Is negative regulation of IP-10 production Important in Cell Biology?
Negative regulation of IP-10 production is important because IP-10 is a central mediator of immune cell trafficking and a biomarker of disease severity. In chronic HIV infection, elevated CXCL10 is associated with viremia and immune activation, and its negative regulator SLAMF7 is critical for controlling IFN-α-driven CXCL10 production. In COVID-19, IP-10 levels predict mortality risk, highlighting the clinical need to understand how IP-10 production is restrained. Moreover, IL-4-mediated suppression of IP-10 in macrophages demonstrates that negative regulation is a physiological anti-inflammatory mechanism. Thus, GO:0071659 is a focal point for therapeutic strategies aiming to modulate chemokine gradients in infection and autoimmunity.
• Controls immune cell recruitment by limiting CXCL10 gradients.
• Modulates chronic inflammation in HIV and other persistent infections.
• Predicts COVID-19 mortality risk, linking negative regulation to disease outcome.
• Provides a mechanism for anti-inflammatory cytokines such as IL-4.
• Involves negative regulators like SLAMF7 and SHIP-1 that are potential drug targets.
• Influences macrophage antimicrobial functions through PTP1B.
• Relevant to autoimmune diseases where IP-10 is overproduced.
• Guides development of CRISPR models to dissect causal genes.
• Connects tryptophan metabolism and immune activation via IDO-derived metabolites.
• Offers biomarkers for monitoring therapeutic efficacy in inflammatory diseases.
What Happens During negative regulation of IP-10 production?
Initiation by Interferon Signaling
In simple terms: Interferons turn on the IP-10 gene, and negative regulation starts by interfering with this signal.
IP-10 production is primarily induced by type I and type II interferons through the JAK-STAT pathway. Negative regulation of IP-10 production can begin at the receptor level, where regulators such as SHIP-1 modulate IFN-induced signaling in human monocytes. SLAMF7 is a critical negative regulator of IFN-α-mediated CXCL10 production in chronic HIV infection, acting as a checkpoint on this initiation step.
Transcriptional Suppression
In simple terms: Some signals block the transcription factors that would otherwise turn on the IP-10 gene.
IL-4 suppresses IP-10 gene expression in murine macrophages by interfering with transcriptional activation. This represents a direct negative regulation at the promoter level, reducing CXCL10 mRNA synthesis. The anti-inflammatory action of IL-4 in contact sensitivity further supports its role in dampening chemokine production.
Post-transcriptional and Signaling Modulation
In simple terms: Even after the gene is turned on, other proteins can shorten the message or block downstream signals.
PTP1B negatively regulates STAT1-independent Pseudomonas aeruginosa killing by macrophages, indicating that phosphatases can modulate inflammatory outputs including chemokine production. SHIP-1 differentially regulates IgE-induced IL-10 and antiviral responses, affecting the balance of cytokines that control CXCL10. These post-transcriptional and signaling events contribute to the overall reduction of IP-10 protein levels.
Integration with Metabolic Cues
In simple terms: Metabolites from the gut microbiome can influence immune activation and possibly IP-10 regulation.
Microbial and indoleamine-2,3-dioxygenase-derived tryptophan metabolites are associated with immune activation in healthy adults. Although direct links to IP-10 negative regulation are not fully established, this suggests that metabolic signals may fine-tune chemokine production. Such integration highlights the complexity of GO:0071659 in vivo.
Key Genes Involved in GO:0071659 negative regulation of IP-10 production
The following genes and proteins have been experimentally implicated in the negative regulation of IP-10 production or in related inflammatory pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLAMF7 | Negative regulator of IFN-α-mediated CXCL10 production | Critical for controlling chronic HIV immune activation |
| SHIP-1 (INPP5D) | Modulates IFN and IgE signaling in monocytes | Differentially regulates IL-10 and antiviral responses |
| IL-4 | Suppresses IP-10 gene expression in macrophages | Anti-inflammatory cytokine model |
| PTP1B (PTPN1) | Phosphatase that negatively regulates macrophage killing | Links to STAT1-independent pathways |
| STAT1 | Transcription factor for IFN-induced genes | Central to IP-10 induction, target of negative regulation |
| CXCL10 (IP-10) | Chemokine ligand | The production of which is negatively regulated |
| IDO1 | Tryptophan metabolism enzyme | Associated with immune activation |
| IFN-α | Type I interferon | Induces CXCL10, target of negative regulation |
| IFN-γ | Type II interferon | Potent inducer of IP-10 |
| IRF1 | Interferon regulatory factor | Transcription factor for CXCL10 |
| NF-κB | Transcription factor | Inflammatory pathway cross-talk |
| SOCS1 | Suppressor of cytokine signaling | Potential negative regulator of IFN signaling |
| SOCS3 | Suppressor of cytokine signaling | Modulates STAT pathways |
| IL-10 | Anti-inflammatory cytokine | Regulated by SHIP-1, may affect IP-10 |
| TNF-α | Pro-inflammatory cytokine | Can synergize with IFN for IP-10 induction |
| TLR4 | Pattern recognition receptor | Upstream of inflammatory chemokines |
| miR-21 | MicroRNA | Potential post-transcriptional regulator (generic) |
How Is negative regulation of IP-10 production Regulated?
Negative regulation of IP-10 production is controlled by multiple layers of signaling. SHIP-1 acts as a negative regulator of IFN-α-mediated CXCL10 production in chronic HIV infection, and its differential effects on IL-10 and antiviral responses highlight its central role. IL-4 provides a classical anti-inflammatory signal that suppresses IP-10 gene expression in macrophages. PTP1B negatively regulates macrophage function, suggesting phosphatase-mediated control of inflammatory chemokine output. Additionally, tryptophan metabolites from the microbiome are associated with immune activation, potentially influencing IP-10 regulation. These pathways collectively tune the magnitude and duration of IP-10 production.
negative regulation of IP-10 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLAMF7 | HIV immune activation | SLAMF7 knockout monocytes |
| SHIP-1 | Chronic HIV, IgE-mediated inflammation | SHIP-1 knockout human monocytes |
| IL-4 | Contact sensitivity, inflammation | IL-4 treated murine macrophages |
| PTP1B | Pseudomonas aeruginosa infection | PTP1B knockout macrophages |
| IDO1 | Immune activation, tryptophan metabolism | IDO1 knockout models |
HIV Infection and Chronic Immune Activation
In early HIV-1 infection, IP-10 levels are associated with viremia, and SLAMF7 is a critical negative regulator of IFN-α-mediated CXCL10 production. Loss of this negative regulation may contribute to persistent immune activation and disease progression. Therefore, GO:0071659 is directly relevant to HIV pathogenesis and potential therapeutic targeting.
COVID-19 Severity and Mortality
Clinical features predicting COVID-19 mortality risk include elevated IP-10, underscoring the importance of negative regulation in restraining excessive chemokine responses. Dysregulated IP-10 production is a hallmark of severe COVID-19, and understanding its negative regulation could inform prognosis and treatment.
Inflammatory and Autoimmune Conditions
IL-4-mediated suppression of IP-10 gene expression demonstrates a physiological anti-inflammatory mechanism that is relevant to contact sensitivity and other inflammatory disorders. Defects in negative regulation may lead to excessive IP-10 and tissue damage. Thus, GO:0071659 is a candidate pathway for anti-inflammatory intervention.
From negative regulation of IP-10 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLAMF7 negatively regulate CXCL10 in HIV? | SLAMF7 knockout in primary monocytes |
| How does SHIP-1 modulate IFN-induced CXCL10? | SHIP-1 knockout or knockdown in human monocytes |
| Can IL-4 suppress IP-10 in macrophages? | IL-4 treatment of murine macrophages |
| Does PTP1B regulate macrophage chemokine output? | PTP1B knockout macrophages |
| What is the role of metabolic cues in IP-10 regulation? | IDO1 knockout or metabolite treatment |
| Can CRISPR activation rescue IP-10 suppression? | CRISPRa overexpression of negative regulators |
How to Study the negative regulation of IP-10 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene loss effects on IP-10 | Identify negative regulators |
| RNA-seq | CXCL10 mRNA levels | Transcriptional suppression |
| ELISA | Secreted IP-10 protein | Quantify negative regulation |
| Flow cytometry | Intracellular IP-10 | Single-cell analysis |
| Metabolomics | Tryptophan metabolites | Link to immune activation |
| Western blot | STAT1 phosphorylation | Signaling modulation |
| qPCR | Gene expression | Validation of regulators |
CRISPR Knockout Screening
CRISPR knockout screens can identify genes whose loss increases IP-10 production, revealing negative regulators. For example, SLAMF7 was identified as a critical negative regulator of IFN-α-mediated CXCL10 production in chronic HIV infection. Such screens are powerful for unbiased discovery of GO:0071659 components.
Transcriptional and Secreted Protein Assays
RNA-seq and ELISA are used to measure CXCL10 mRNA and secreted IP-10 protein, respectively. IL-4-mediated suppression of IP-10 gene expression was demonstrated using these methods in murine macrophages. These assays are essential for quantifying the extent of negative regulation.
Flow Cytometry and Imaging
Flow cytometry can assess intracellular IP-10 and surface markers in immune cells. SHIP-1 differentially regulates IgE-induced IL-10 and antiviral responses in human monocytes, which can be monitored by flow cytometry. Imaging of chemokine gradients in tissues provides spatial context for negative regulation.
Metabolomics and Microbiome Analysis
Associations of microbial and IDO-derived tryptophan metabolites with immune activation can be studied using metabolomics. These approaches may uncover metabolic influences on IP-10 negative regulation, linking GO:0071659 to host-microbe interactions.
How CRISPR Can Be Used to Study GO:0071659 negative regulation of IP-10 production
Knockout
CRISPR knockout of candidate negative regulators such as SLAMF7 or SHIP-1 can test whether their loss increases IP-10 production. This approach directly validates GO:0071659 components in relevant cell types.
Point Mutation
Point mutations can be introduced into signaling domains of regulators like SHIP-1 to dissect phosphoinositide binding or catalytic activity. Such models help define the molecular requirements for negative regulation of IP-10.
Knock-in
Knock-in of tagged versions of CXCL10 or its regulators allows tracking of protein localization and interactions. This can reveal where negative regulation occurs within the cell.
Overexpression
Overexpression of negative regulators such as SLAMF7 or IL-4 can suppress IP-10 production, confirming sufficiency. CRISPR activation (CRISPRa) enables tunable overexpression to study dose-dependent effects.
How EDITGENE Supports negative regulation of IP-10 production Research
Researchers studying negative regulation of IP-10 production-related genes often need to determine whether a candidate gene is causally involved in suppressing CXCL10. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional studies with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of IP-10 production research.
Frequently Asked Questions About negative regulation of IP-10 production
What is GO:0071659?
GO:0071659 is the Gene Ontology term for negative regulation of IP-10 production, defined as any process that stops, prevents, or reduces the production of the chemokine IP-10 (CXCL10).
What is IP-10?
IP-10, also known as CXCL10, is an interferon-inducible chemokine that recruits activated T cells and is a biomarker of immune activation.
What genes are involved in negative regulation of IP-10 production?
Key genes include SLAMF7, SHIP-1 (INPP5D), IL-4, and PTP1B, which have been shown to suppress CXCL10 production or related inflammatory pathways.
How is IP-10 production negatively regulated in HIV?
In chronic HIV infection, SLAMF7 acts as a critical negative regulator of IFN-α-mediated CXCL10 production, helping to control immune activation.
What role does IL-4 play in IP-10 regulation?
IL-4 suppresses IP-10 gene expression in murine macrophages, providing an anti-inflammatory mechanism to limit chemokine production.
Can CRISPR be used to study negative regulation of IP-10?
Yes, CRISPR knockout, knock-in, and overexpression models enable causal testing of candidate regulators such as SLAMF7 and SHIP-1.
Why is negative regulation of IP-10 important in COVID-19?
IP-10 levels predict COVID-19 mortality risk, so understanding its negative regulation may inform prognosis and therapeutic strategies.
What diseases are associated with dysregulated IP-10 production?
HIV infection, COVID-19, and inflammatory conditions such as contact sensitivity are associated with altered IP-10 regulation.
How does SHIP-1 regulate IP-10?
SHIP-1 differentially regulates IgE-induced IL-10 and antiviral responses in human monocytes, impacting the cytokine milieu that controls CXCL10.
What experimental methods are used to study GO:0071659?
Common methods include CRISPR screens, RNA-seq, ELISA, flow cytometry, and metabolomics to measure IP-10 and identify regulators.
Conclusion
GO:0071659, negative regulation of IP-10 production, is a critical biological process that restrains the chemokine CXCL10 to prevent excessive immune activation. Key regulators such as SLAMF7, SHIP-1, IL-4, and PTP1B have been identified through studies in HIV, COVID-19, and inflammatory models. Understanding these mechanisms offers therapeutic opportunities to modulate chemokine gradients in infectious and autoimmune diseases. EDITGENE provides advanced CRISPR tools to accelerate research into this important pathway.
References
- 1. Kouhpayeh H. 2022. Clinical features predicting COVID-19 mortality risk.. Eur J Transl Myol 32(2) PMID: 35421918
- 2. Lee S et al.. 2015. Interferon-inducible protein 10 (IP-10) is associated with viremia of early HIV-1 infection in Korean patients.. J Med Virol 87(5):782-9 PMID: 25678246
- 3. O'Connell P et al.. 2019. SLAMF7 Is a Critical Negative Regulator of IFN-α-Mediated CXCL10 Production in Chronic HIV Infection.. J Immunol 202(1):228-238 PMID: 30530590
- 4. Deng W et al.. 1994. Mechanisms of IL-4-mediated suppression of IP-10 gene expression in murine macrophages.. J Immunol 153(5):2130-6 PMID: 8051417
- 5. Gautam SC et al.. 1992. Anti-inflammatory action of IL-4. Negative regulation of contact sensitivity to trinitrochlorobenzene.. J Immunol 148(5):1411-5 PMID: 1538125
- 6. Solleti SK et al.. 2024. SHIP-1 differentially regulates IgE-induced IL-10 and antiviral responses in human monocytes.. bioRxiv PMID: 38370636
- 7. Riazati N et al.. 2022. Associations of microbial and indoleamine-2,3-dioxygenase-derived tryptophan metabolites with immune activation in healthy adults.. Front Immunol 13:917966 PMID: 36248784
- 8. Yue L et al.. 2020. PTP1B negatively regulates STAT1-independent Pseudomonas aeruginosa killing by macrophages.. Biochem Biophys Res Commun 533(3):296-303 PMID: 32958258
